

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 September 2021 (02.09.2021)



(10) International Publication Number
WO 2021/173964 A1

(51) International Patent Classification:

A61K 35/14 (2015.01) A61K 38/19 (2006.01)
A61K 35/17 (2015.01) A61K 38/20 (2006.01)
A61K 38/18 (2006.01)

(21) International Application Number:

PCT/US2021/019861

(22) International Filing Date:

26 February 2021 (26.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/983,416 28 February 2020 (28.02.2020) US
63/074,841 04 September 2020 (04.09.2020) US
63/144,853 02 February 2021 (02.02.2021) US

(71) Applicant: **KSQ THERAPEUTICS, INC.** [US/US]; 610 Main Street North, 4th Floor, Cambridge, MA 02139 (US).

(72) Inventors: **BENSON, Micah**; 27 Glenburn Road, Arlington, MA 02476 (US). **TUBO, Noah, Jacob**; 6 Wildflower Drive, Sutton, MA 01590 (US). **COLLETTI, Nicholas, John**; 309 Allston Street, Apt. 8, Boston, MA 02135 (US). **LAMOTHE, Robert, Andrew**; 21 Ellery Street, Cambridge, MA 02138 (US). **KRYUKOV, Gregory, V.**; 11 Cappy Circle, Newton, MA 02465 (US). **SCHLABACH, Michael**; 301 Pleasant Street, Belmont, MA 02478 (US). **ARLAUCKAS, Sean, Philip Leary**; c/o KSQ Therapeu-

tics, Inc., 610 Main Street North, 4th Floor, Cambridge, MA 02139 (US).

(74) Agent: **DIPIETRANTONIO, Heather, J.** et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS FOR ACTIVATION AND EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES




FIG. 1A

(57) Abstract: Methods for activating and expanding TILs using unconventional cytokines are provided. These methods include techniques for activating and expanding TILs using streamlined approaches, including one-step approaches, approaches using agonists for stimulation, approaches more suitable for clinical manufacturing, and approaches without the requirement of feeder cells, are provided. Compositions of expanded populations of TILs are also provided, in addition to populations of expanded TILs enriched in central memory T cell phenotype.

WO 2021/173964 A1

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))